Triflusal

Triflusal

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	B01AC18 (WHO)
Identifiers
IUPAC name 2-acetyloxy-4-(trifluoromethyl)benzoic acid
CAS Number	322-79-2 Y
PubChem CID	9458
DrugBank	DB08814 Y
ChemSpider	9086 Y
UNII	1Z0YFI05OO
ChEMBL	ChEMBL1332032 Y
CompTox Dashboard (EPA)	DTXSID8045305
ECHA InfoCard	100.005.726
Chemical and physical data
Formula	C10H7F3O4
Molar mass	248.157 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(=O)Oc1cc(ccc1C(=O)O)C(F)(F)F
InChI InChI=1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16) Y Key:RMWVZGDJPAKBDE-UHFFFAOYSA-N Y

Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a derivative of acetylsalicylic acid (ASA; Aspirin) in which a hydrogen atom on the benzene ring has been replaced by a trifluoromethyl group. Trade names include Disgren, Grendis, Aflen and Triflux.^[1]

Triflusal has multiple mechanisms of action that contribute to the effect of the drug. It is a COX-1 inhibitor. It also inhibits the activation of nuclear factor k-B, which in turn regulates the expression of the mRNA of the vascular cell adhesion molecule-1 needed for platelet aggregation. Additionally, Triflusal preserves vascular prostacyclin which yields an anti-platelet effect. Triflusal also blocks phosphodiesterase, increasing cAMP concentration as well as can increase nitric oxide synthesis in neutrophils.